| ATCT Main | Editorial Board | Current Issue | Infocus Roundtable | ATCT CME Activities | Download | Search |
This activity is sponsored by Albert Einstein College of Medicine &
Montefiore Medical Center
Presenter: Rafael Rosell, MD
Date of release: March 2006
Termination: February 2007
Estimated time to complete this activity: 1 hour
A CME-accredited activity on the internet as an audio slide-show presentation.
(59 Slides)
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
Rafael Rosell, MD, is Chief of the Medical Oncology Service and Scientific Director of Oncology Research at the Catalan Institute of Oncology in Barcelona. He received his medical training in Spain, and served as a Foreign Research Fellow at the Foundation for Promotion of Cancer Research in Tokyo, Japan, in 1998.
Dr. Rosell is Chairman of the Spanish Lung Cancer Group, a Member of the Board of Directors of the International Association for the Study of Lung Cancer, a Member of the Protocol Review Committee of the European Organization for Research and Treatment of Cancer (EORTC), and a Member of the Scientific Program Committee of the American Society of Clinical Oncology (ASCO). He is the recipient of the ALCASE Award of Excellence (Alliance for Lung Cancer Advocacy, Support, and Education).
A frequent contributor to the literature, Dr. Rosell has authored more than 300 articles published in peer-reviewed medical or scientific journals.
Professor of Medicine and Molecular Pharmacology
Chief, Division of Medical Oncology
Albert Einstein College of Medicine
Chairman, Department of Oncology
Montefiore Medical Center
Bronx, New York
Roman Perez-Soler, MD, is an internationally recognized expert in the development of new anticancer therapies and new delivery systems for anticancer agents, with a particular focus on lung cancer. Over the years, he has been involved in the development of many new anticancer agents, including the topoisomerase I inhibitors, taxanes, new nucleoside analogs, non-cross–resistant platinum compounds, and, more recently, the EGFR tyrosine kinase inhibitors and proteasome inhibitors.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Dr. Rosell does not have any significant financial arrangement or affiliations with commercial or equipment companies.
He will discuss investigational use of anticancer agents during his presentation.
Dr. Perez-Soler receives grant/research support from OSI Pharmaceuticals and the NIH and serves as a consultant to OSI Pharmaceuticals, Genentech, Amgen, AstraZeneca Pharmaceuticals, Novartis, Eli Lilly, Bristol-Myers Squibb, Alza, and Transave. He also serves on the speakers’ bureau for Genentech and Eli Lilly. Dr. Perez-Soler is a stock shareholder in OSI Pharmaceuticals, Genentech, Amgen, AstraZeneca Pharmaceuticals, Novartis, Eli Lilly, and Transave.
The recent introduction of targeted therapies has afforded new treatment options for patients with NSCLC. Clinical investigation is now delineating the utility of these novel agents, alone or in combination with standard therapies, to enhance survival. As oncologists begin to add these first targeted therapies to the treatment armamentarium for NSCLC, other targeted approaches are being developed and tested.
In this session, Dr. Rafael Rosell reviews the molecular targets in NSCLC and provides current clinical information about available targeted therapies for patients with NSCLC. His presentation includes an update on the development of other novel compounds and second-generation agents, such as monoclonal antibodies and antiangiogenic agents.
This discussion will provide physicians with current information on potential treatment options for NSCLC.
This educational activity is designed for clinical oncologists and research scientists. Others who may benefit include health care professionals involved in cancer clinical trials and development of new anticancer therapies.
After reading the article, “Promising Targeted Modalities for NSCLC,” the learner should be able to:
Outline the current standard approach to the treatment of patients with NSCLC
Describe how targeted and traditional therapies for NSCLC can be integrated
Provide details of the key clinical trials of the targeted therapies currently available for treatment of patients with NSCLC
List the advantages and challenges associated with targeted therapies for patients with NSCLC
Portions of the CME Media may not be viewable without Macromedia Flash Player. Version 6.0 or higher is required. If needed, Macromedia Flash Player 8.x is available for free download from www.macromedia.com.
The post-test and evaluation are available for download upon completion of the audio-slide show. Download and print the post-test and evaluation. Circle the correct answer to each question on the test.
Print and FAX the post-test and evaluation to 718-798-2336, or mail to:
CCME
3301 Bainbridge Avenue
Bronx, NY 10467
Photocopies are acceptable. You will receive notification of your test results within 4 weeks. If you have successfully completed the test (7 or more correct answers), you will receive a certificate for 1 Category 1 Credit toward the AMA Physician’s Recognition Award by mail. There is no fee for participating in this continuing medical education activity.
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates each educational activity for a maximum of 1 Category 1 Credit toward the AMA Physician’s Recognition Award. Each physician should claim those credits that he/she actually spent in the educational activity.
This CME activity was planned and produced in accordance with the ACCME Essentials.
